Velocity Fund launches InClinica from acquired CRO IndiPharm


Pittsburgh’s Velocity Fund Partners has picked up CRO IndiPharm for an undisclosed amount, renaming the Philadelphia firm InClinica.

InClinica, as it is now called, boasts a specialty in early and midstage trials from Pennsylvania, and it also has locations in the U.K., Israel, Malaysia and Singapore. Velocity is looking to cash in on this global reach, positioning the CRO for growth down the road, according to a release.

With the acquisition, IndiPharm founder and president Edward Brennan will serve as InClinica’s chief medical officer, and Michael Fare will be chief operating officer and chief technical officer.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Bloomberg writes in an overview that one of Indipharm’s strategies is to provide Western biopharmas “a gateway for conducting clinical trials in India.” Currently, the company is managing a global Phase III clinical trial for lung cancer.

“InClinica’s existing global footprint and experience in early drug and device development and clinical trials, combined with Velocity’s unique experience and contacts in both healthcare and life sciences, will enable InClinica to provide companies with significant value in all clinical phases,” said Velocity Managing Partner Ken Melani.

“Many drugs fail to advance during clinical research for reasons unrelated to efficacy or safety,” Fare said. “An experienced clinical CRO can anticipate challenges and plan ahead, ensuring a smoother progression through clinical development.”

- here's the release

Related Article:
WCCT Global and cancer CRO Medelis to combine under merger deal


Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.